Appili Therapeutics Inc. (TSX: APLI)
Health Care · Pharmaceuticals · CA
CA$0.02
0.00% today · -25.0% 1Y
Appili Therapeutics Inc. (TSX: APLI) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $1.44M and employs 7 people.
Over the last twelve months the share price has lost 25.0%, trading between 0.01 and 0.04.
Tweenvest scores Appili Therapeutics Inc. across four factors: quality 7/100, value 63/100. Its strongest factor is value.
APLI price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.44M
- Revenue (TTM)
- $254.96K
- P/E
- —
- EPS
- -0.04
- Dividend yield
- —
- Beta (5Y)
- -0.20
- 52-week high
- CA$0.04
- 52-week low
- CA$0.01
- Avg volume (3M)
- —
- Shares outstanding
- 132.37M
- Employees
- 7
- Next earnings
- —
About Appili Therapeutics Inc.
Appili Therapeutics Inc., a Canadian biopharmaceutical firm headquartered in Halifax and founded in 2015, specializes in sourcing and advancing innovative treatments to address critical gaps in infectious disease medicine. The company's diverse pipeline includes Favipiravir, utilized for pandemic influenza and COVID-19, and the clinical-stage antifungal ATI-2307, which targets cryptococcal meningitis and invasive candidiasis. Other programs feature ATI-1503, a new class of gram-negative targeting antibiotics; ATI-1501, a taste-masked liquid oral metronidazole suspension; ATI-1801, a novel topical formulation of paromomycin for treating cutaneous leishmaniasis; and ATI-1701, a live-attenuated vaccine designed for Francisella tularensis. Additionally, Appili maintains a strategic collaboration with AiPharma Global Holdings LLC for the ongoing development of Avigan/Reeqonus (favipiravir).
- ISIN
- CA03783R1073
- Founded
- 2015
- Listed since
- Jun 25, 2019
- Exchange
- The Toronto Stock Exchange
- Currency
- CAD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.11T | $1,257.13 | +0.82% |
| Johnson & JohnsonNYSE: JNJ | $658.00B | $272.92 | -0.04% |
| Merck & Co., Inc.NYSE: MRK | $371.70B | $154.01 | +2.22% |
| Roche Holding AGSWX: ROP | $368.80B | CHF373.80 | +0.92% |
| Novartis AGSWX: NOVN | $300.52B | CHF126.76 | -0.52% |
| AstraZeneca PLCLSE: AZN | $256.25B | £124.76 | +3.02% |
| Novo Nordisk A/SCPSE: NOVO B | $206.64B | Dkr299.25 | -0.53% |
| Pfizer Inc.NYSE: PFE | $159.42B | $28.44 | +1.68% |
Figures last refreshed Aug 18, 2026.